Life
Merck's HIV Prevention Pill: Potential for Low-Cost Generic Production
Merck's experimental HIV prevention pill could be produced for under $5 annually, prompting calls for urgent licensing of generics to enhance accessibility for at-risk populations.
Editorial Staff
1 min read
Merck's new HIV prevention pill has been assessed for its potential affordability, with estimates suggesting a production cost of less than $5 per year.
Research advocates emphasize the need for Merck to license generic production urgently, which could facilitate broader access to this crucial medication.
The implications of such a low-cost option could significantly impact at-risk populations, enhancing public health outcomes through improved accessibility.